MeSH term
Frequency | Condition_Probility | Antigens, CD/*analysis | 8 | 1.0 |
Blotting, Southern | 4 | 0.0 |
Comparative Study | 8 | 0.0 |
Female | 76 | 0.0 |
Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 2 | 25.0 |
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 2 | 6.0 |
Humans | 153 | 0.0 |
Immunohistochemistry | 59 | 0.0 |
Infant | 9 | 0.0 |
Male | 90 | 0.0 |
Middle Aged | 64 | 0.0 |
Receptors, Antigen, B-Cell/*analysis | 5 | 83.0 |
Polymerase Chain Reaction | 24 | 0.0 |
Aged | 45 | 0.0 |
Aged, 80 and over | 17 | 0.0 |
B-Lymphocytes/*pathology | 4 | 9.0 |
Biopsy | 10 | 0.0 |
Cell Differentiation | 7 | 0.0 |
Epstein-Barr Virus Infections/complications/pathology | 2 | 100.0 |
Immunoenzyme Techniques | 11 | 0.0 |
In Situ Hybridization | 18 | 0.0 |
Phenotype | 9 | 0.0 |
Pneumothorax, Artificial/adverse effects | 2 | 100.0 |
T-Lymphocytes/*pathology | 2 | 2.0 |
Tumor Markers, Biological/metabolism | 8 | 2.0 |
Adult | 58 | 0.0 |
Remission Induction | 5 | 0.0 |
Antigens, CD/*genetics | 4 | 1.0 |
B-Lymphocytes/immunology | 4 | 0.0 |
Base Sequence | 7 | 0.0 |
Child | 31 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Mutation | 2 | 0.0 |
Receptors, Antigen, B-Cell/*genetics | 3 | 27.0 |
Research Support, Non-U.S. Gov't | 63 | 0.0 |
Cytogenetic Analysis | 2 | 1.0 |
DNA, Neoplasm/analysis | 13 | 1.0 |
Flow Cytometry | 13 | 0.0 |
Tumor Markers, Biological/analysis | 15 | 2.0 |
Acute Disease | 6 | 0.0 |
Adolescent | 26 | 0.0 |
Antigens, CD/analysis | 20 | 1.0 |
Bone Marrow Cells/immunology | 4 | 10.0 |
*Immunophenotyping | 3 | 1.0 |
Diagnosis, Differential | 28 | 1.0 |
Fatal Outcome | 11 | 1.0 |
Antigens, CD3/analysis | 6 | 2.0 |
Antigens, CD30/analysis | 3 | 8.0 |
Antigens, CD45/analysis | 2 | 0.0 |
English Abstract | 6 | 0.0 |
Prognosis | 8 | 0.0 |
Receptors, Antigen, B-Cell/analysis | 12 | 66.0 |
Sialoglycoproteins/analysis | 2 | 5.0 |
Survival Analysis | 5 | 0.0 |
Child, Preschool | 19 | 0.0 |
Combined Modality Therapy | 5 | 0.0 |
Neoplasm Proteins/analysis | 4 | 1.0 |
Neoplasm Recurrence, Local | 2 | 0.0 |
Cyclophosphamide/administration & dosage | 3 | 1.0 |
Doxorubicin/administration & dosage | 4 | 2.0 |
Immunophenotyping | 39 | 1.0 |
Prednisone/administration & dosage | 4 | 4.0 |
Vincristine/administration & dosage | 4 | 2.0 |
Epstein-Barr Virus Infections/complications | 3 | 25.0 |
DNA Fingerprinting | 2 | 1.0 |
Karyotyping | 6 | 0.0 |
Biological Markers/analysis | 5 | 0.0 |
Gene Rearrangement | 5 | 1.0 |
Immunoglobulin Variable Region/genetics | 4 | 3.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 2 | 1.0 |
Vimentin/analysis | 2 | 0.0 |
Lymph Nodes/pathology | 5 | 1.0 |
Tumor Markers, Biological | 5 | 1.0 |
Antigens, CD/biosynthesis | 3 | 0.0 |
Radiotherapy | 2 | 6.0 |
Herpesvirus 4, Human/genetics/isolation & purification | 4 | 30.0 |
RNA, Viral/analysis | 4 | 1.0 |
RNA-Binding Proteins/analysis | 4 | 20.0 |
*Ribosomal Proteins | 4 | 16.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Treatment Outcome | 6 | 0.0 |
Antigens, Neoplasm/*analysis | 3 | 0.0 |
Antigens, Surface/*analysis | 2 | 1.0 |
Leukemia, Myeloid/classification/diagnosis/pathology | 2 | 100.0 |
Animals | 15 | 0.0 |
Antigens, CD/*metabolism | 5 | 0.0 |
Bone Marrow/pathology | 3 | 0.0 |
Receptors, Antigen, B-Cell/*metabolism | 6 | 7.0 |
B-Lymphocytes/*immunology | 7 | 0.0 |
Lymphoma, B-Cell/*immunology | 2 | 5.0 |
Follow-Up Studies | 3 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 4 | 2.0 |
Retrospective Studies | 9 | 0.0 |
Immunophenotyping/*methods | 3 | 4.0 |
Reference Values | 2 | 0.0 |
*Antigens, CD | 2 | 0.0 |
Cell Lineage | 8 | 1.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Hodgkin Disease/*pathology | 2 | 16.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Time Factors | 3 | 0.0 |
Herpesvirus 4, Human/isolation & purification | 2 | 3.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 8 | 1.0 |
B-Lymphocytes/chemistry/pathology | 2 | 25.0 |
Antigens, CD20/*metabolism | 3 | 33.0 |
Clone Cells | 4 | 0.0 |
Liver Transplantation/*adverse effects | 2 | 13.0 |
*Bone Marrow Transplantation | 2 | 0.0 |
Leukemic Infiltration | 2 | 15.0 |
Antigens, CD/metabolism | 12 | 1.0 |
DNA Nucleotidylexotransferase/metabolism | 2 | 10.0 |
Biological Markers | 3 | 0.0 |
Case-Control Studies | 2 | 0.0 |
Antigens, CD20/analysis | 4 | 9.0 |
Antigens, CD5/analysis | 2 | 4.0 |
Immunoglobulins, Heavy-Chain/genetics | 8 | 5.0 |
Immunoglobulins, Light-Chain/genetics | 2 | 5.0 |
Survival Rate | 3 | 0.0 |
Amino Acid Sequence | 5 | 0.0 |
Molecular Sequence Data | 9 | 0.0 |
*Mutation | 2 | 0.0 |
Tumor Stem Cells/pathology | 3 | 9.0 |
Dogs | 2 | 0.0 |
Antigens, CD20/*analysis | 2 | 28.0 |
*Gene Rearrangement | 2 | 0.0 |
Paraffin Embedding | 7 | 2.0 |
Chromosome Disorders | 2 | 0.0 |
Antigens, CD20/biosynthesis | 2 | 11.0 |
Antigens, CD3/biosynthesis | 3 | 5.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis | 2 | 1.0 |
Receptors, Antigen, B-Cell/biosynthesis | 2 | 50.0 |
Antigens, Neoplasm/analysis | 5 | 1.0 |
Receptors, Antigen, B-Cell/analysis/genetics | 2 | 100.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Antigens, CD34/analysis | 2 | 0.0 |
Neprilysin/analysis | 3 | 5.0 |
B-Lymphocytes/*physiology | 2 | 1.0 |
Mice | 5 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 6 | 0.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Lymphoma, AIDS-Related/immunology/*pathology | 2 | 66.0 |
Alternative Splicing | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Tumor Cells, Cultured | 5 | 0.0 |
Methotrexate/administration & dosage | 2 | 2.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Recurrence | 4 | 0.0 |
Biopsy, Needle | 3 | 0.0 |
Hyperplasia | 2 | 0.0 |
Lymphoma, B-Cell/genetics/*pathology | 2 | 20.0 |
World Health Organization | 2 | 2.0 |
Antigens, Viral/analysis | 2 | 2.0 |
Herpesvirus 4, Human | 2 | 1.0 |
Viral Matrix Proteins/analysis | 2 | 14.0 |
Dura Mater/*pathology | 2 | 40.0 |
Gene Expression | 3 | 0.0 |
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 3 | 4.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Antigens, CD/*biosynthesis/genetics | 2 | 3.0 |
B-Lymphocytes/cytology | 2 | 2.0 |
DNA Nucleotidylexotransferase/*analysis | 2 | 20.0 |
Flow Cytometry/*methods | 4 | 1.0 |
Hematopoietic Stem Cells/*metabolism | 2 | 1.0 |
Receptors, Antigen, B-Cell/*biosynthesis/genetics | 2 | 50.0 |
Antineoplastic Agents/therapeutic use | 3 | 1.0 |
B-Lymphocytes/pathology | 2 | 2.0 |
Antigens, CD/genetics | 2 | 1.0 |
B-Lymphocytes/*metabolism | 2 | 1.0 |
Sequence Alignment | 2 | 0.0 |
Leukemia, Pre-B-Cell/genetics/*pathology | 2 | 66.0 |
*Tumor Cells, Cultured | 2 | 2.0 |
Gene Rearrangement, B-Lymphocyte, Heavy Chain/genetics | 3 | 25.0 |
Precipitin Tests | 2 | 0.0 |
Receptors, Antigen, B-Cell/*physiology | 3 | 3.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 2 | 0.0 |
Antigens, CD/analysis/immunology | 2 | 4.0 |
Cross Reactions | 2 | 0.0 |
*Lymphocyte Activation | 3 | 0.0 |
Phosphorylation | 2 | 0.0 |
Immunoglobulins/analysis | 2 | 0.0 |
Herpesvirus 4, Human/*isolation & purification | 2 | 5.0 |
*Chromosome Aberrations | 2 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Immunohistochemistry/*methods | 2 | 2.0 |
Organ Transplantation/*adverse effects | 2 | 18.0 |
DNA Primers/chemistry | 2 | 0.0 |
Lymphoma, B-Cell/chemistry/immunology/*pathology | 2 | 66.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 2 | 0.0 |
Peroxidase/analysis | 2 | 3.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
*Genes, Immunoglobulin | 2 | 1.0 |
Antibodies, Monoclonal/*diagnostic use | 2 | 0.0 |
Paraffin | 2 | 4.0 |
Antigens, Differentiation, B-Lymphocyte/*analysis | 2 | 3.0 |
Membrane Glycoproteins/*metabolism | 2 | 0.0 |
*Cell Adhesion Molecules | 2 | 0.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Spectral Karyotyping | 2 | 20.0 |
*Translocation, Genetic | 2 | 0.0 |
Membrane Glycoproteins/*genetics | 2 | 0.0 |
Antigens, CD45/metabolism | 2 | 2.0 |
Translocation, Genetic | 2 | 0.0 |
Antibodies, Monoclonal/*therapeutic use | 2 | 0.0 |
B-Lymphocytes/metabolism/*pathology | 2 | 28.0 |
